Cardiology Supplement cardiovascular musculoskeletal

CoQ10 (Ubiquinol)

koh-EN-zime Q-ten

Formula C59H90O4 MW 863.34 g/mol PubChem CID 5281915 →

IUPAC Ubiquinone-10

SMILES CC1=C(C(=O)C(=C(C1=O)OC)OC)C/C=C(\C)/CC/C=C(\C)/CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C

2D structure

C+ 50.0/100

Dimension Scores

Human Outcome (30%)

5.0

Biomarker Relevance (20%)

6.0

Signal Source Quality (15%)

5.0

Organ Specificity (15%)

5.0

Translational Maturity (20%)

5.0

Evidence Summary

CoQ10 has the longest clinical evidence history of any longevity supplement. A 2024 meta-analysis found CoQ10 supplementation significantly reduced major adverse cardiovascular events. The Q-SYMBIO trial showed reduced mortality in heart failure patients.

However, most evidence is in disease populations (heart failure, statin users), not healthy aging. The translation from disease treatment to longevity intervention is assumed, not proven.

Safety Considerations

Well-tolerated. May reduce effectiveness of warfarin. Statin users have depleted CoQ10 — supplementation is well-supported in this population.

Evidence Signals (0)

🔒

Create a free account to see signal-level evidence grades.

Create a free account

Products Containing CoQ10 (Ubiquinol)

No commercial products are currently listed for this molecule.

Regulatory Intelligence

🔒

Subscribe to access FDA enforcement history, third-party verification status, and regulatory risk assessment.

This evidence profile reflects publicly available research as of March 15, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.